Search Results for: stem cells for ms

Gaetan Burgio New Data & Theory on NgAgo versus CRISPR

/ / 3 Comments
Burgio-Figure-5-e1469980662937

By Gaetan Burgio CRISPR/Cas9 genome editing has dramatically changed our way to perform biological experiments. While highly efficient and easy to use, one limitation with CRISPR/Cas9 mediated genome editing technology is the occurrence of off-target effects and the restriction of the PAM recognition sequence. Many modifications from the original system have been proposed to improve […]

Gaetan Burgio New Data & Theory on NgAgo versus CRISPR Read More »

Yamanaka’s baby turns 10: ten IPS cell hot button bullet points

/
Nobel Laureate Shinya Yamanaka, the first to produce induced pluripotent stem cells

Has it really been 10 years since induced pluripotent stem cells (aka IPS cells or IPSC) came onto the scene in the stem cell field? Yes, it was a decade ago that now Nobel Laureate Shinya Yamanaka (山中伸弥) published that seminal Cell paper on reprogramming to make mouse IPS cells and then human IPS cells

Yamanaka’s baby turns 10: ten IPS cell hot button bullet points Read More »

REGROW Act 2.0 still no-go with big risks to patients & field

/ / 10 Comments
Mark-Kirk-REGROW-Act

The REGROW Act is a bill that seeks to lessen the regulatory burden to accelerate getting stem cells to patients more quickly, but it over-reaches so much that it would almost certainly do harm to patients and maybe to the stem cell field as a whole. The REGROW Act, which is sponsored by Senator Mark

REGROW Act 2.0 still no-go with big risks to patients & field Read More »

Austin Smith talk at ISSCR 2016: a ground state inhibitor pathway

/ / 1 Comment
ISSCR-2016-packed-house-e1466961505769

ISSCR 2016’s first plenary session is focused on stem cells & cancer. I was really excited about this one even before the meeting as this topic is a major focus of my own lab. Here’s the lineup for this plenary with great expertise in stem cells & cancer from across the globe: President’s Address: Sean Morrison, Children’s

Austin Smith talk at ISSCR 2016: a ground state inhibitor pathway Read More »

New Herbert lab Nature paper reinforces mitochondrial replacement Achilles heel

/ / 1 Comment
Herbert-mitochondria-Nature-paper

Today a new Nature paper from Dr. Mary Herbert’s group in the UK has found a key problem with mitochondrial replacement therapy that fits with data from others. Mitochondrial replacement data The goal of preventing mitochondrial disease using various kinds of genome transfer technologies is a noble one, but mitochondrial replacement therapy has faced a

New Herbert lab Nature paper reinforces mitochondrial replacement Achilles heel Read More »

NgAgo a-go-go: main bullet points on upstart CRISPR challenger

/
NgAgo-1-e1464201441475

The gene editing technology CRISPR has been arguably the top story in the biomedical world in the last two years, but going forward there is a CRISPR challenger in upstart gene editing technology NgAgo. For more background on NgAgo and the key first published paper on its genetic modification characteristics see my post here.  In the comments on that

NgAgo a-go-go: main bullet points on upstart CRISPR challenger Read More »

Haruko Obokata (小保方 晴子) website posts dubious STAP cell validation data

/ / 3 Comments
STAP-cell-Obokata-2016

Haruko Obokata is most well-known for her role as first author of the now retracted two STAP cell Nature papers. These manuscripts claimed to have made pluripotent and even totipotent stem cells simply by stressing cells out with acid treatment or in other ways. Nobody else could get this method to work to create the so-called

Haruko Obokata (小保方 晴子) website posts dubious STAP cell validation data Read More »

Huge clinical trial fees allowed by FDA at times, details often secret

/ / 9 Comments
Monopoly1-300x2851

Why can there be huge clinical trial fees for participants? I am often critical of for-profit stem cell clinics on this blog for numerous reasons. For instance, one thing that concerns me greatly about these clinics is that they charge patients to get experimental “treatments” that have not been proven to be safe or effective. But

Huge clinical trial fees allowed by FDA at times, details often secret Read More »

UK should freeze mitochondrial replacement as Egli paper ID’s serious problem

/ / 1 Comment
Egli-genetic-drift-paper

An important new Cell Stem Cell paper from Dieter Egli’s lab points to an inherent, serious problem with so-called 3-person IVF or mitochondrial replacement technology that warrants putting an immediate hold on all efforts to use it in humans. I have pasted the graphical abstract from the paper below. For years a few of us scientists and

UK should freeze mitochondrial replacement as Egli paper ID’s serious problem Read More »

Will new gene editing tech NgAgo challenge CRISPR?

/ / 17 Comments
NgAgo1-1024x437-1-e1463852392677

2020 Update: early NgAgo reports have been mostly discredited and there is doubt on its function as a gene-editing method. What could be better than CRISPR for gene editing? A new genetic modification technology called NgAgo has some researchers really excited. How does it compare to CRISPR? I’ll admit it that as a scientist who works on

Will new gene editing tech NgAgo challenge CRISPR? Read More »